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Background: Obstructive sleep apnea occurs as a result of increased collapsibility of the upper airway. Overnight
fluid displacement from the legs to the neck causes pharyngeal narrowing and increased apnea severity. Sodium
intake is associated with apnea severity. We hypothesized that interventions that decrease bodily fluid content
might reduce the severity of sleep apnea.
Methods/design: This is a randomized clinical trial including men with an apnea-hypopnea index greater than 30
events/hour, previously diagnosed by full-night in-laboratory polysomnography. A total of 54 men will be included
and randomly assigned to three groups: Diuretic (n = 18), sodium-restricted diet (n = 18), and control (n = 18). The
intervention will last one week. Intention-to-treat and per-protocol analyses will be performed. The diuretic group
will receive combined spironolactone 100 mg plus furosemide 20 mg daily, taken in the morning. The diet group
will receive a regimen with a maximum intake of 3 g of sodium per day. The control group will receive a placebo
pill and will maintain all eating habits while keeping a recall diary of their dietary behavior. The primary outcome
measure will be change in apnea-hypopnea index. The secondary outcome measures will be variations of: anthropometric
and bioelectrical impedance variables, office blood pressure, respiratory variables from in-home level III polysomnography,
excessive daytime sleepiness, glycolipid profile, C-reactive protein, 24 h urinary variables, and adverse events.
Discussion: Despite the high efficacy of continuous positive airway pressure to reverse upper airway obstruction in sleep
apnea, partial adherence to this form of treatment reduces its efficiency. Thus, additional forms of treating apnea need to
be investigated. If the results of this proof-of-concept trial show that decreases in bodily fluid content, either by diuretic or
dietary intervention, reduces the severity of sleep apnea, further investigation will be necessary before these results can
be translated and adopted as an adjunct apnea therapy.
Trial registration: clinicaltrials.gov NCT01945801.
Keywords: Body fluids, Diuretic, Furosemide, Sleep apnea, Sodium-restricted diet, Spironolactone, TreatmentBackground
Obstructive sleep apnea is a disorder characterized by re-
petitive collapse of the upper airway during sleep [1]. Its
prevalence is increasing [2], reaching, in one study, 32% of
the general adult population [3]. One reason for this grow-
ing prevalence of sleep apnea is the obesity epidemic, since
obesity and neck circumference are risk factors for apnea.* Correspondence: cintiazfiori@gmail.com
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unless otherwise stated.Sleep apnea, however, is also observed in non-obese people.
In large samples, half of patients with apnea have body
mass indexes below 27.6 kg/m2 [4].
Rostral fluid shift, that is, a shift of fluid from the
lower to the upper body, produces a significant increase
in neck circumference, pharyngeal resistance, and upper
airway collapsibility [5-10]. Wearing elastic stockings
during the day reduces the apnea-hypopnea index byis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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patients with venous insufficiency [12]. Preventing fluid
retention might reduce overnight fluid shift from the
legs to the neck.
Diuretics given to patients with uncontrolled hyperten-
sion reduced their apnea-hypopnea index by 16%, an effect
size of 0.3 [13]. In resistant hypertension, spironolactone re-
duced patients’ apnea-hypopnea index by approximately
50%, an effect size of 1.2 [14]. Also, diuretics improve
sleep-disordered breathing and increase pharyngeal caliber
in patients with severe obstructive sleep apnea and diastolic
heart failure [15].
Fluid retention is proportional to sodium intake. Pa-
tients with sleep apnea have significantly greater sodium
intake than patients without. In receiver operating char-
acteristic (ROC) curve analysis, a sodium intake above a
cutoff value of 2.4 g/day predicted moderate to severe
sleep apnea (area under the ROC curve of 0.78) [16].
The upper limit of recommended sodium intake for
healthy adults is 2.3 g/day [17]. Bibbins-Domingo et al.
project that a reduction of dietary salt could halve the
annual number of new cases of coronary heart disease,
stroke, and myocardial infarction, and the number of
deaths from any cause in the United States [18]. It is
possible that part of the projected effect of salt restric-
tion may be due to the effect of fluid retention on ob-
structive sleep apnea severity.
Continuous positive airway pressure (CPAP) is highly
efficacious in treating obstructive sleep apnea. Many pa-
tients, however, find it difficult to tolerate its use. Poor
adherence to CPAP treatment leads to reduced control
of associated morbidities [19]. Reductions in blood pres-
sure levels are seen only when CPAP use is above
5.6 hours per night [20]. Alternatives to CPAP treatment
have problems of incomplete efficacy and adherence.
Mandibular advancement oral appliances are similar to
CPAP in controlling hypertension [21]. Various surgical
approaches have diverse results [22].
Therapy of sleep apnea, therefore, is not a settled
issue. Broadening comprehension of the pathogenesis of
obstructive sleep apnea may help in the search for new
and better tolerated treatments for the millions of people
with sleep apnea.
We hypothesized that in the usual patient with apnea,
without such conditions causing fluid retention as heart,
renal, or venous failure, decreasing fluid retention using
diuretics and a sodium-restricted diet might change sleep
apnea severity. To test this hypothesis, we will conduct a
trial in which the primary outcome measure is the apnea-
hypopnea index. The secondary outcome measures are an-
thropometric and bioelectrical impedance variables, blood
pressure, respiratory variables in-home polysomnography,
excessive daytime sleepiness, glycolipid profile, C-reactive
protein, 24 h urinary variables, and adverse events.Rationale
Apnea severity has been associated with overnight fluid
displacement from the legs to the neck. Peripharyngeal
fluid accumulation predisposes patients to upper airway
collapse. Diuretics or a sodium-restricted diet offer
therapeutic potential for sleep apnea by preventing fluid
retention.
Research question
Is a diuretic or a sodium-restricted diet capable of redu-








 Men aged from 18 to 60 years;
 Full-night in-laboratory polysomnography with
apnea-hypopnea index greater than 30 per hour in
the past three months;
 Body mass index less than 35 kg/m2;
 Informed consent.
Exclusion criteria
 Already receiving treatment for sleep apnea,
including CPAP;
 Heart failure, any New York Heart Association class;
 More than 50% of the apnea events being of central
origin;
 Any chronic renal disease;
 Peripheral venous or lymphatic insufficiency;
 Use of diuretics and substances with action on the
central or peripheral nervous system, such as
benzodiazepines, hypnotics, anticonvulsants,
antidepressants, appetite suppressants,
amphetamines, antiparkinson agents, muscle
relaxants, bronchodilators;
 Stroke within the past 6 months or with
incapacitating sequelae;
 Any physical, mental, or social condition impairing
the ability to participate in the trial.
Sample size
Sample size calculations were performed for repeated
measures analysis of variance using G*Power software
3.1.9.2 [23]. Hypothesizing an effect size of 0.25 for a
power of 90% at P alpha < 0.05, for three groups, a sam-
ple size of at least 18 in each arm of the study was
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follow-up, extra volunteers will be enrolled to compen-
sate. Losses will be included in the intention-to-treat but
not in the per-protocol analyses.
Randomization process
Randomly permuted blocks of six numbers, obtained
from randomization.com [24], will be employed. Patients
will be assigned to one of the three groups by a re-
searcher not otherwise involved in the protocol.
Blinding
The researchers taking measurements for either primary
or secondary outcome measures, as described herein,
will be blind to the group assignment. On completion of
the study, volunteers will be asked to which group they
believe they were assigned, to allow assessment of the
blinding success [25].
The nutritionist, who delivers the diets, the only non-
blinded intervention, will not be aware of the pills supplied
to the unmodified diet groups and will not be involved in
other steps of the protocol. The scoring of the apnea-
hypopnea index will be performed remotely via the internet
by a third-party certified scorer. The blinding code will be
broken at the end of the study or earlier by request of regu-
latory committees or in the case of adverse events in con-
nection with the group assignment.
Recruitment
A list of patients who recently underwent polysomno-
graphy at the affiliated sleep laboratory and signed a
form consenting to participate in research will be gener-
ated. Those patients with an apnea-hypopnea index
greater than 30 events/hour will be selected and con-
tacted by telephone. If they have no prescription by their
physicians to start treatment in the next week, they will
be invited to participate. The acceptors will be asked to
visit the research center where the informed consent
process will be conducted.
Data management
The data will be entered in a password-protected com-
puter system by researchers not otherwise involved in
the protocol. The system performs a range check of the
data values entered. A second person will make a visual
check, comparing original documents with entered data
to correct discrepancies. The database is backed up each
15 minutes in a computer located remotely at the uni-
versity and in an international data safety company.
Statistical methods
Outcomes will be analyzed by intention-to-treat and
per-protocol. A low attrition rate is expected, since the
interventions are of short duration and minimal risk.Missing data will be considered as missing. Data imput-
ation will not be employed.
Normally distributed data will be presented as means
and standard deviation. Non-normally distributed data will
be displayed as median and interquartile range. Natural
logarithm transformation of the apnea-hypopnea index in
events/h will be employed to correct its non-normal distri-
bution in analyses that assume normal data distribution.
The significance of the differences between intervention
groups will be tested by chi-squared test for categorical
variables and generalized estimating equations method,
followed by pairwise comparisons with the sequential
Bonferroni correction for continuous variables. Logistic
and linear regression models will be used to adjust results
for age and body mass index. Results with a P value lower
than 0.05 for alpha error will be considered statistically
significant. Statistical analyses will be performed using
SPSS software (SPSS Inc., Chicago, IL, USA).Monitoring
No committee will be monitoring the data. All analyses
will be performed at the end of the study.Study measurements
Description of interventions, comparison groups, and
follow-up
The patients will be allocated to a combination of medi-
cation and diet intervention. A detailed description of
the combinations of pill plus diet interventions is shown
in Figure 1.
Identical pills and flasks will contain either active drug
(spironolactone 100 mg plus furosemide 20 mg) or cellu-
lose. The diet interventions will be either instruction to
maintain unchanged the present alimentary habits or a
diet restricting sodium intake to a maximum of three
grams per day.
The inception of the one-week intervention will occur
only after volunteers confirm that in this specific week they
will not participate in social events, gatherings, celebrations,
travels, visits to restaurants, in such way that the adhesion
to the dietary instructions will be made easier.
The sodium-restricted diet will enforce the following
rules: (1) Do not use salt in cooking; (2) Do not use the
salt shaker; (3) To flavor foods, use spices, herbs, and
other seasonings, such as olive oil, lemon, herbs, garlic,
onion, parsley and chives, instead of salt; (4) Do not eat
any industrialized food, such as sauces, soups, sausages,
canned food, frozen, salted snacks, cheese, salami or sau-
sages; (5) Eat fresh salads and vegetables; (6) Do not add
high-sodium seasonings, such as soy sauce; (7) Eat fruit
for dessert; do not eat baked desserts. The complete diet-
ary rules will be delivered to each volunteer in a four-page
handout.
Figure 1 Flow diagram of the study design.
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The study was approved by the Ethics Committee of the
Hospital de Clínicas de Porto Alegre under the number
130272. This committee is accredited by the Office of
Human Research Protection as an Institutional Review
Board (IRB0000921). The study has been registered under
the number NCT01945801 at www.clinicaltrials.gov. All
participants will be asked to sign the approved informed
consent form prior to participation in the study.
Authorship eligibility will follow the guidelines of the
International Committee of Medical Journal Editors.
Professional writers will not be used. The trial results
will be published in a high impact international journal.
The investigators will communicate trial results to par-




 Number of apneas and hypopneas per hour of sleep
(apnea-hypopnea index)
Secondary outcomes Adverse events
 Anthropometry (body weight and height; neck,
waist, hip, ankle, and calf circumferences)
 Bioelectrical impedance variables
 Urinary electrolytes and metabolites
 Office blood pressure
 Respiratory variables from the type III portable
polysomnography
 Excessive daytime somnolence
 Glycolipid profile
 Inflammatory marker
Follow-up and duration of the study
There will be two visits at the clinical research center,
one before (baseline) and one after (follow-up) the one-
week pill plus diet intervention.
Assessment of outcomes
Sleep respiratory variables
The apnea-hypopnea index in events/hour will be mea-
sured at baseline and follow-up nights by type III port-
able polysomnography. Minimum oxygen saturation will
also be analyzed. The equipment employed in the study
(SOMNOcheck effort, Weinmann GmbH, Hamburg,
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showed diagnostic performance similar to in-laboratory
attended polysomnography [26].
Adverse events
The adverse events will be investigated by open ques-
tions, including general symptoms, and by specific ques-
tions regarding symptoms potentially related with the
drugs used in the trial, as dizziness, cramps, dehydration,
and hypotension. The rate of adverse effects will be de-
termined by comparing the frequency of adverse events
in the drug arm with in the placebo arm.
Bioelectrical impedance
The body composition will be determined in the morn-
ing, while fasting, with a tetrapolar bioelectrical imped-
ance device (Biodynamics, model 450, WA, USA)
[27,28], at baseline and follow-up visits. The measure-
ments will be made after the blood sample collection, in
fasting, without ingesting any liquid.
Blood pressure
The average office blood pressure will be measured ac-
cording to the American Heart Association guidelines
[29]. The same validated oscillometric device (OMRON
CP-705) [30] will be employed at baseline and follow-up
visits.
Excessive daytime sleepiness
The volunteers will complete the Epworth sleepiness
scale [31] to evaluate somnolence. The same model of
form will be presented at baseline and follow-up visits.
Biochemical evaluation
The collection of blood samples for biochemical evaluation
will be performed in all subjects at baseline and follow-up
visits. Enrollees will be asked to arrive at the center early in
the morning in fasting. Blood samples will be drawn dir-
ectly in five different sampling tubes. The samples will be
rushed to the lab to measure plasma levels of: aldosterone,
renin, ultrasensitive C-reactive protein, cholesterol total,
high density lipoprotein-cholesterol, triglycerides, and glu-
cose. At each visit the individuals will return the refriger-
ated container previously handed to them for 24-hour
urinary collection. Dosages of urinary aldosterone, sodium,
potassium, urea, and creatinine will be obtained.
Discussion
This experiment is designed to test the hypothesis that
abating fluid retention may affect apnea severity. In the
drug arm, the intervention will be an association of a
loop diuretic with a potassium-sparing aldosterone-
antagonist agent in moderate doses, to ensure a negative
balance of sodium and water. In the diet arm, a strictlow-sodium diet will be implemented. To serve as con-
trol, the trial will have a placebo arm.
Besides the effect on the apnea-hypopnea index, the study
will measure potential mediators and consequences of these
interventions. If the hypothesis regarding fluid retention is
confirmed, further trials will be necessary to verify whether
the effect is due to fluid shift from the legs to the neck. For
this, measurement of overnight fluid shift by bioelectrical
impedance will be necessary.
The therapeutic efficiency and efficacy of diuretic and
diet interventions will not be tested. It will remain to be
confirmed whether the effect is maintained for years and if
it is attainable with lower doses of diuretics and with diets
less restricted in sodium, that is, more agreeable to the pa-
tients. Clinical trials with large samples and long term
follow-up will be necessary to clarify these questions.
Trial status
At the time of manuscript submission, the enrollment of
volunteers is ongoing.
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